Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents develops manufactures and commercializes medicines for patients with serious diseases. The company focuses on eye diseases allergic and inflammatory conditions cancer cardiovascular and metabolic disorders neurological diseases hematologic conditions infectious diseases and rare disorders. Its strategy rests on a strong foundation in scientific research and drug development using proprietary technologies and builds on that foundation with clinical development manufacturing and commercial capabilities. The goal is to continue advancing as an integrated multi product biotechnology company providing important medicines for preventing and treating human diseases.

Regeneron generates revenue primarily from the sale of its approved products and from collaboration agreements with partners. Product sales include ophthalmology therapies such as EYLEA and EYLEA HD immunology agents like Dupixent and Kevzara oncology treatments such as Libtayo cardiovascular drugs like Praluent and Evkeeza and other marketed items. The company also earns collaboration revenue from profit sharing and royalty arrangements with Sanofi Bayer and other partners. In addition it receives revenue from the sale of bulk drug material to collaborators and from milestone payments tied to development programs.

The company operates through the following segments.

• This segment encompasses the discovery of new drug targets the development of biologic therapies the manufacturing of clinical and commercial supplies and the commercialization of approved medicines worldwide.

Regeneron holds a strong position in several therapeutic areas where its products compete with established biopharmaceutical firms. In ophthalmology its EYLEA franchise faces competition from products such as Vabysmo Lucentis Avastin and various biosimilars. In immunology Dupixent competes with drugs like Dupixent's rivals including Adbry Cibinqo Rinvoq and others. In oncology Libtayo competes with checkpoint inhibitors such as Keytruda Opdivo Tecentriq and others. The company's competitive advantages stem from its proprietary technology platforms including the Trap technology and the VelociSuite suite which enable rapid discovery and production of fully human antibodies and bispecific molecules. These capabilities support a deep pipeline and allow for differentiated mechanisms of action.

Regeneron sells its products to wholesalers specialty distributors pharmacies hospitals government agencies physicians and other healthcare providers. The company's revenue is concentrated with two major customers each accounting for more than ten percent of total gross product revenue and together representing about seventy seven percent of sales. While the specific names of these customers are not disclosed they are understood to be large distributors that serve the broader healthcare market.